Adi Osovsky
General Counsel at ITEOS THERAPEUTICS, INC.
Network origin in Adi Osovsky first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 18 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Adi Osovsky via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| IMMUNOMEDICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
Novellus Systems, Inc.
 Novellus Systems, Inc. Industrial MachineryProducer Manufacturing Novellus Systems, Inc. manufactures and services advanced automated wafer fabrication systems. The company was founded by Brad Mattson on April 11, 1984 and is headquartered in Fremont, CA. | Industrial Machinery | Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
UBS Securities LLC
 UBS Securities LLC Investment ManagersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Managers | Analyst-Equity Corporate Officer/Principal | |
| SANOFI | Biotechnology | Corporate Officer/Principal | |
Jazz Pharmaceuticals, Inc.
 Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Analyst-Equity | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree | |
| University of Pennsylvania | College/University | Corporate Officer/Principal | |
| College of the Holy Cross (Massachusetts) | College/University | Undergraduate Degree | |
The Johns Hopkins Hospital, Inc.
 The Johns Hopkins Hospital, Inc. Hospital/Nursing ManagementHealth Services The Johns Hopkins Hospital, Inc. provides healthcare services. The hospital is affiliated to the Johns Hopkins University School of Medicine. It offers inpatient and outpatient health services that include general medicine, emergency and trauma care, pediatrics, maternity, and senior care. The company was founded in 1889 and is headquartered in Baltimore, MD. | Hospital/Nursing Management | Corporate Officer/Principal | |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Private Equity Investor | |
| University of California, Los Angeles | College/University | Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Graduate Degree | |
| The Catholic University of America | College/University | Undergraduate Degree | |
| The Johns Hopkins University | College/University | Corporate Officer/Principal | |
| Yale University | College/University | Doctorate Degree | |
| Wellesley College | College/University | Undergraduate Degree | |
| Astrazeneca AG | Corporate Officer/Principal | ||
| JAZZ PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Operating Officer Director/Board Member Founder | |
| JOUNCE THERAPEUTICS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| The Johns Hopkins University School of Medicine | College/University | Doctorate Degree | |
| CRISPR THERAPEUTICS AG | Biotechnology | Chief Tech/Sci/R&D Officer | |
| University of Pennsylvania Medical Center | College/University | Graduate Degree | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Director/Board Member | |
Suzhou Connect Biopharma Co. Ltd.
 Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Pharmaceuticals: Major | Director/Board Member | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
| 89BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Pharmaceuticals: Major | Director/Board Member | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Biotechnology | Director/Board Member | |
| ACRIVON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| DAY ONE BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| CONNECT BIOPHARMA HOLDINGS LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
| MINERALYS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| TANGO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
| CANBRIDGE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor |
Statistics
International
| United States | 39 |
| United Kingdom | 5 |
| Switzerland | 3 |
| China | 3 |
| France | 2 |
Sectoral
| Health Technology | 28 |
| Consumer Services | 12 |
| Finance | 7 |
| Commercial Services | 4 |
| Producer Manufacturing | 2 |
Operational
| Director/Board Member | 79 |
| Corporate Officer/Principal | 38 |
| Independent Dir/Board Member | 38 |
| Chief Executive Officer | 16 |
| Undergraduate Degree | 15 |
Most connected contacts
| Insiders | |
|---|---|
| Ann Rhoads | 19 |
| Aaron Davis | 19 |
| Matt Roden | 18 |
| Derek DiRocco | 17 |
| Tony Ho | 15 |
| David Hallal | 15 |
| Detlev Biniszkiewicz | 12 |
| Jill DeSimone | 12 |
| Robert Iannone | 11 |
| Tim van Hauwermeiren | 9 |
| Matthew Call | 9 |
| Michel Detheux | 8 |
| Bronson Crouch | 6 |
| Yvonne McGrath | 5 |
| Joanne Lager | 4 |
- Stock Market
- Insiders
- Adi Osovsky
- Company connections
